{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal CYP-001",
            "NStudiesAvail": 430108,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2016-000070-38"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Proportion of participants who show a Complete Response (absence of any signs or symptoms of GvHD) by Day 28",
                              "Proportion of participants who show a Partial Response (improvement in the severity of GvHD by at least one grade compared to baseline) by Day 28",
                              "Proportion of participants who survive until Day 28",
                              "Proportion of participants who show a Complete Response by Day 100",
                              "Proportion of participants who show a Partial Response by Day 100",
                              "Proportion of participants who survive until Day 100"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Complete Response by Day 28",
                              "Partial Response by Day 28",
                              "Overall Survival at Day 28",
                              "Complete Response by Day 100",
                              "Partial Response by Day 100",
                              "Overall Survival at Day 100"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "28 days",
                              "28 days",
                              "28 days",
                              "100 days",
                              "100 days",
                              "100 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02923375"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assessment of safety",
                              "Circulating biomarker of inflammation",
                              "Not hospitalised, with resumption of normal activities = 1; Not hospitalised, but unable to resume normal activities = 2; Hospitalised, not requiring supplemental oxygen = 3; Hospitalised, requiring supplemental oxygen = 4; Hospitalised, requiring humidified nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both = 5; Hospitalised, requiring invasive mechanical ventilation, extracorporeal membrane oxygenation or both = 6; Death = 7",
                              "Assessment of respiratory dysfunction",
                              "Assessment of respiratory dysfunction",
                              "Assessment of respiratory dysfunction",
                              "Assessment of respiratory dysfunction",
                              "Assessment of respiratory dysfunction",
                              "Number of days from the time of initiating unassisted breathing to D28, assuming survival for at least 48 hours after initiating unassisted breathing and continued unassisted breathing to D28",
                              "Quality of life assessment",
                              "Disability assessment"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence and severity of treatment-emergent adverse events",
                              "Change in C-reactive protein (CRP) levels",
                              "Proportional differences between groups on the Clinical Improvement Scale",
                              "Changes in P/F ratio",
                              "Changes in respiratory rate",
                              "Changes in oxygenation index",
                              "Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)",
                              "Changes in positive end-expiratory pressure",
                              "Ventilator-free days",
                              "Proportional differences between groups on the SF-36",
                              "Proportional differences between groups on the mini mental state examination"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "28 days",
                              "7 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days",
                              "28 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04537351"
                        ]
                  }
            ]
      }
}